We recently published 10 Easy Double-Digit Gainers. Roivant Sciences Ltd. (NASDAQ:ROIV) was one of the best performers last ...
Hosted on MSN
Why Roivant Sciences Stock Was Slipping on Monday
The biotech published an earnings report that fell short of expectations. It whiffed on both the top and bottom lines. 10 stocks we like better than Roivant Sciences › Commercial-stage biotech Roivant ...
The average one-year price target for Roivant Sciences (NasdaqGS:ROIV) has been revised to $32.44 / share. This is an ...
Roivant Sciences stock: recent performance snapshot Roivant Sciences (ROIV) has drawn fresh attention after a strong recent run, with the share price at $25.82 and positive returns over the past week, ...
Roivant Sciences ROIV will release its quarterly earnings report on Thursday, 2025-05-29. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Roivant Sciences to ...
Organon is broadening its presence in dermatology with a deal to acquire Dermavant, a company whose main asset is a commercialized plaque psoriasis drug that could soon expand its approval to include ...
Biopharmaceutical company Roivant Sciences (NASDAQ:ROIV) reported earnings for the third quarter of 2024 on Monday, Feb. 10, that topped analysts' consensus estimates. Q3 revenue of $9.02 million ...
Roivant Sciences stock has risen significantly since my initial coverage in 2022, with a positive market response to fiscal year 2025 Q1 earnings. Roivant operates by creating "nimble subsidiaries to ...
The biotech published an earnings report that fell short of expectations. It whiffed on both the top and bottom lines. Roivant reported that its revenue for the period was slightly under $2.2 billion, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results